. Author manuscript; available in PMC: 2022 Aug 1.

Published in final edited form as: Pediatr Diabetes. 2021 Apr 20;22(5):749–757. doi: 10.1111/pedi.13209

Table 1:

The relationships of C-peptide, and autoantibodies for 99 individuals clinically diagnosed with T1D

	Autoantibody status
	GADA-65 ≥30 (n=53)	IA-2A ≥30 (n=27)	Both autoantibodies (n=12)	Either/both autoantibodies (n=69)	Neither autoantibodies (n=30)
C-peptide <0.8 ng/mL (<0.26 nmol/L) (n=68)	37 (54.4%)	20 (29.4%)	9 (13.2%)	49 (72.1%)	19 (27.9%)
¹C-peptide 0.8–3.1 ng/mL (0.26–1.03 nmol/L)¹ (n=30)	15 (50.0%)	6 (20.0%)	2 (6.7%)	19 (63.3%)	11 (36.7%)
C-peptide >3.1 ng/mL (>1.03 nmol/L) (n=1)	1 (100.0%)	1 (100.0%)	1 (100.0%)	1 (100.0%)	0 (0.0%)

^1:

Normal Range